These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25054664)

  • 1. Bevacizumab for acute neurologic deterioration in patients with glioblastoma.
    Kaley T; Nolan C; Carver A; Omuro A
    CNS Oncol; 2013 Sep; 2(5):413-8. PubMed ID: 25054664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
    Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
    J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
    Reardon DA; Herndon JE; Peters KB; Desjardins A; Coan A; Lou E; Sumrall AL; Turner S; Lipp ES; Sathornsumetee S; Rich JN; Sampson JH; Friedman AH; Boulton ST; Bigner DD; Friedman HS; Vredenburgh JJ
    Br J Cancer; 2012 Oct; 107(9):1481-7. PubMed ID: 23037712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated progression of glioblastoma after treatment with bevacizumab.
    Bloch O; Safaee M; Sun MZ; Butowski NA; McDermott MW; Berger MS; Aghi MK; Parsa AT
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1795-801. PubMed ID: 23706614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
    Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A
    Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
    Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF
    J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
    Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A
    J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for bevacizumab in the treatment of glioblastoma?
    Chi AS; Chamberlain MC
    Oncologist; 2013; 18(10):1080-2. PubMed ID: 24056893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
    Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
    Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
    Nghiemphu PL; Liu W; Lee Y; Than T; Graham C; Lai A; Green RM; Pope WB; Liau LM; Mischel PS; Nelson SF; Elashoff R; Cloughesy TF
    Neurology; 2009 Apr; 72(14):1217-22. PubMed ID: 19349600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.